In addition, the expression of MyD88 was notably decreased by both the engineered bacteria and exenatide (1.54 versus 1.03 and 0.84, p < 0.01), while EcN-GLP-1 did not increase the expression of p-NFκB/NFκB (1.93 versus 1.70, p > 0.05) as exenatide do (1.93 versus 2.35, p < 0.01), and none treatments had an obvious effect on the expression of TLR-4 compared to the T2DM mice (1.38 versus 0.99 and 0.96, p > 0.05) (Figure 4(e)). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.